{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:47:07Z","timestamp":1787028427184,"version":"build-2736575974"},"reference-count":132,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Secondary osteoporosis is a common clinical problem faced by bone specialists, with a higher frequency in men than in women. One of several causes of secondary osteoporosis is hematological disease. There are numerous hematological diseases that can have a deleterious impact on bone health. In the literature, there is an abundance of evidence of bone involvement in patients affected by multiple myeloma, systemic mastocytosis, thalassemia, and hemophilia; some skeletal disorders are also reported in sickle cell disease. Recently, monoclonal gammopathy of undetermined significance appears to increase fracture risk, predominantly in male subjects. The pathogenetic mechanisms responsible for these bone loss effects have not yet been completely clarified. Many soluble factors, in particular cytokines that regulate bone metabolism, appear to play an important role. An integrated approach to these hematological diseases, with the help of a bone specialist, could reduce the bone fracture rate and improve the quality of life of these patients.<\/jats:p>","DOI":"10.3390\/ijms21103538","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T02:43:42Z","timestamp":1589769822000},"page":"3538","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Hematological Diseases and Osteoporosis"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-9606","authenticated-orcid":false,"given":"Agostino","family":"Gaudio","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Xourafa","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Rapisarda","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-3778","authenticated-orcid":false,"given":"Luca","family":"Zanoli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Santo","family":"Signorelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Castellino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"key":"ref_1","first-page":"421746","article-title":"Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells","volume":"2015","author":"Sasso","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1748-1716.2011.02385.x","article-title":"Osteocytes: Central conductors of bone biology in normal and pathological conditions","volume":"204","author":"Neve","year":"2012","journal-title":"Acta Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2010-0067","article-title":"Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss","volume":"95","author":"Gaudio","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","first-page":"20187","article-title":"Importance of osteocyte-mediated regulation of bone remodelling in inflammatory bone disease","volume":"150","author":"Intemann","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"ref_5","first-page":"221","article-title":"Relationships between osteoprotegerin, receptor activator of the nuclear factor kB ligand and serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus","volume":"56","author":"Gaudio","year":"2014","journal-title":"Panminerva Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.3892\/mmr.2017.6390","article-title":"Sclerostin is a possible candidate marker of arterial stiffness: Results from a cohort study in Catania","volume":"15","author":"Gaudio","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/joim.12369","article-title":"Osteoporosis: The evolution of a diagnosis","volume":"277","author":"Lorentzon","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"NIH (2001). Consensus Development Panel on Osteoporosis Prevention D Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285, 785\u2013795.","DOI":"10.1001\/jama.285.6.785"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-15-0118","article-title":"Management of endocrine disease: Secondary osteoporosis: Pathophysiology and management","volume":"173","author":"Mirza","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bone.2018.02.019","article-title":"Bone and blood interactions in human health and disease","volume":"119","author":"Wu","year":"2019","journal-title":"Bone"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1096\/fj.14-259085","article-title":"Erythropoietin directly stimulates osteoclast precursors and induces bone loss","volume":"29","author":"Liron","year":"2015","journal-title":"FASEB J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.3390\/nu7042324","article-title":"Chronic iron deficiency as an emerging risk factor for osteoporosis: A hypothesis","volume":"7","author":"Toxqui","year":"2015","journal-title":"Nutrients"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: A population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: A population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1038\/bcj.2015.71","article-title":"Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance","volume":"5","author":"Piot","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","article-title":"Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u03b1 levels in patients with MGUS","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2013-05-505776","article-title":"Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"123","author":"Farr","year":"2014","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/clinchem\/47.4.686","article-title":"Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis","volume":"47","author":"Woitge","year":"2001","journal-title":"Clin. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02230356","article-title":"Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and non symptomatic myeloma","volume":"15","author":"Laroche","year":"1996","journal-title":"Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/bloodadvances.2017010454","article-title":"Bone disease in monoclonal gammopathy of undetermined significance: Results from a screened population-based study","volume":"21","author":"Thorsteinsdottir","year":"2017","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: A systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2018","journal-title":"J. Bone Miner. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00223-008-9145-2","article-title":"The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance","volume":"82","author":"Pepe","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network","volume":"99","author":"Palumbo","year":"2014","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ejh.12923","article-title":"Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies","volume":"99","author":"Zagouri","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Vallet, S., Filzmoser, J.M., Pecherstorfer, M., and Podar, K. (2018). Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040202"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1158\/0008-5472.CAN-08-0402","article-title":"CC-chemokine ligand 20\/macrophage inflammatory protein-3\u03b1 and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions","volume":"68","author":"Giuliani","year":"2008","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.182.5.1461","article-title":"Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors","volume":"182","author":"Udagawa","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","article-title":"Wnt signaling in multiple myeloma: A central player in disease with therapeutic potential","volume":"11","author":"Spaan","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.beha.2005.01.003","article-title":"Cytokines and signal transduction","volume":"18","author":"Hideshima","year":"2005","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and multiple myeloma","volume":"4","author":"Giuliani","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"New Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V96.2.381.014k54_381_383","article-title":"Introduction: The evolving role of bisphosphonate therapy in multiple myeloma","volume":"96","author":"Raje","year":"2000","journal-title":"Blood"},{"key":"ref_48","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane. Database Syst. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"Krebbel","year":"2007","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jbmr.2741","article-title":"The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors","volume":"31","author":"Toscani","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Anderson","year":"2017","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016, pdated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.22125","article-title":"Pediatric-onset mastocytosis: A long term clinical follow-up and correlation with bone marrow histopathology","volume":"53","author":"Uzzaman","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"Gorantla","year":"2005","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","year":"2012","journal-title":"Allergy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","article-title":"Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis","volume":"24","author":"Seitz","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/jbmr.2456","article-title":"Rapid skeletal turnover in radiographic mimic of osteopetrosis might be secondary to systemic mastocytosis [corrected]","volume":"30","author":"Rossini","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000091172","article-title":"Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis","volume":"139","author":"Brittain","year":"2006","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Lnt. Arch. Allergy lmmunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(199710)173:1<10::AID-JCP2>3.0.CO;2-M","article-title":"H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: Evidence obtained by using receptor antago nists in a rat synchronized resorption model","volume":"173","author":"Dobigny","year":"1997","journal-title":"J. Cell Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts","volume":"174","author":"Baroukh","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","article-title":"Bone involvement and osteoporosis in mastocytosis","volume":"34","author":"Rossini","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00223-015-9969-5","article-title":"Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis","volume":"96","author":"Rossini","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"75.e1","DOI":"10.1016\/j.amjmed.2012.07.018","article-title":"Bone complications of mastocytosis: A link between clinical and biological characteristics","volume":"126","author":"Guillaume","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","article-title":"Osteopenia in systemic mastocytosis: Natural history and responses to treatment with inhibitors of bone resorption","volume":"8","author":"Cundy","year":"1987","journal-title":"Bone"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1127.e1","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am. J. Med."},{"key":"ref_81","first-page":"672","article-title":"Mast cells in atherosclerosis as a source of the cytokine RANKL","volume":"44","author":"Ali","year":"2006","journal-title":"Clin. Chem. Lab Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1056\/NEJM198106113042406","article-title":"Relation between erythropoiesis and bone metabolism in thalassemia","volume":"304","author":"Pootrakul","year":"1981","journal-title":"New Engl. J. Med."},{"key":"ref_84","first-page":"773","article-title":"Multicentre study on prevalence of fractures in transfusion dependent thalassemic patients","volume":"11","author":"Ruggiero","year":"1998","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00277-016-2633-y","article-title":"Longitudinal changes of endocrine and bone disease in adults with \u03b2-thalassemia major receiving different iron chelators over 5 years","volume":"95","author":"Poggi","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.1998.01108.x","article-title":"High prevalence of low bone mass in thalassaemia major","volume":"103","author":"Jensen","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4274\/jcrpe.galenos.2018.2018.0074","article-title":"Pathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical Experience","volume":"11","author":"Gaudio","year":"2019","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2008.03.003","article-title":"Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia","volume":"43","author":"Fung","year":"2008","journal-title":"Bone"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bone.2005.10.001","article-title":"Prevalence of fractures among the Thalassemia syndromes in North America","volume":"38","author":"Vogiatzi","year":"2006","journal-title":"Bone"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1359\/jbmr.080505","article-title":"Bone disease in thalassemia: A frequent and still unresolved problem","volume":"24","author":"Vogiatzi","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MPH.0b013e3182841574","article-title":"Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes","volume":"35","author":"Engkakul","year":"2013","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.1995.tb01876.x","article-title":"The contribution of hypogonadism to the development of osteoporosis in thalassemia major: New therapeutic approaches","volume":"42","author":"Anapliotou","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0026-0495(98)90237-2","article-title":"Bone mineral density in prepubertal children with \u03b2-thalassemia: Correlation with growth and hormonal data","volume":"47","author":"Soliman","year":"1998","journal-title":"Metabolism"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2265.2008.03191.x","article-title":"Bone demineralization in adult thalassaemic patients: Contribution of GH and IGF-I at different skeletal sites","volume":"69","author":"Scacchi","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF03344015","article-title":"Osteoporosis and beta-thalassemia major: Role of the IGF-I\/IGFBP-III axis","volume":"25","author":"Lasco","year":"2002","journal-title":"J. Endocrinol. Invest."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.bone.2007.02.020","article-title":"The \u201clively\u201d cytokines network in beta-Thalassemia Major-related osteoporosis","volume":"40","author":"Morabito","year":"2007","journal-title":"Bone"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01352012","article-title":"Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging","volume":"53","author":"Bordat","year":"1993","journal-title":"Calcif. Tissue Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00247-002-0664-0","article-title":"Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: Predominance of osteoporosis and desferrioxamine-induced bone dysplasia","volume":"32","author":"Chan","year":"2002","journal-title":"Pediatr. Radiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/adc.62.5.474","article-title":"Serum 1,25 dihydroxyvitamin D and osteocalcin concentrations in thalassemia major","volume":"62","author":"Dandona","year":"1987","journal-title":"Arch. Dis. Child."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.clinbiochem.2010.04.070","article-title":"Role of genetic pattern on bone mineral density in thalassemic patients","volume":"43","author":"Gaudio","year":"2010","journal-title":"Clin. Biochem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1359\/jbmr.040113","article-title":"Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: New pieces of the puzzle","volume":"19","author":"Morabito","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1055\/s-0032-1312618","article-title":"High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density","volume":"44","author":"Voskaridou","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/j.clinthera.2015.10.001","article-title":"Iron Chelation in Thalassemia Major","volume":"37","author":"Marsella","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s00198-016-3719-z","article-title":"Thalassemia-associated osteoporosis: A systematic review on treatment and brief overview of the disease","volume":"27","author":"Dede","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s001980170079","article-title":"Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major","volume":"12","author":"Lasco","year":"2001","journal-title":"Osteoporos. Int."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/gim.2016.173","article-title":"\u03b2-Thalassemia","volume":"19","author":"Origa","year":"2017","journal-title":"Genet. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/nyas.13041","article-title":"Management of beta-thalassemia-associated osteoporosis","volume":"1368","author":"Giusti","year":"2016","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s42000-018-0019-3","article-title":"The role of biphosphonates in the management of thalassemia-induced osteoporosis: A systematic review and meta-analysis","volume":"17","author":"Tsartsalis","year":"2018","journal-title":"Hormones"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03345587","article-title":"Bisphosphonates in the treatment of thalassemia-associated osteoporosis","volume":"31","author":"Gaudio","year":"2008","journal-title":"J. Endocrinol. Invest."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/bloodadvances.2018023085","article-title":"Denosumab in transfusion-dependent thalassemia osteoporosis: A randomized, placebo-controlled, double-blind phase 2b clinical trial","volume":"2","author":"Voskaridou","year":"2018","journal-title":"Blood Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00774-015-0689-8","article-title":"Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis","volume":"34","author":"Morabito","year":"2016","journal-title":"J. Bone Miner. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/trf.13237","article-title":"Effects of teriparatide retreatment in a patient with \u03b2-thalassemia major","volume":"55","author":"Tournis","year":"2015","journal-title":"Transfusion"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11739-019-02160-x","article-title":"Sickle cell disease: A review for the internist","volume":"14","author":"Pinto","year":"2019","journal-title":"Int. Emerg. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.20541","article-title":"High prevalence and correlates of low bone mineral density in young adults with sickle cell disease","volume":"81","author":"Miller","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4137\/CMED.S24501","article-title":"Predictors of abnormal bone mass density in adult patients with homozygous sickle-cell disease","volume":"8","author":"Garadah","year":"2015","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11657-017-0364-x","article-title":"Evaluation of bone mineral density in children with sickle-cell anemia and its associated factors in the south of Iran: A case-control study","volume":"12","author":"Bordbar","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2018.02.003","article-title":"High bone mineral density in sickle cell disease: Prevalence and characteristics","volume":"110","author":"Ranque","year":"2018","journal-title":"Bone"},{"key":"ref_118","first-page":"813","article-title":"Osteoporosis and osteosclerosis in sickle cell\/beta-thalassemia: The role of the RANKL\/osteoprotegerin axis","volume":"91","author":"Voskaridou","year":"2006","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/0019-5359.40984","article-title":"Secondary osteoporosis due to sickle cell anemia: Do sex steroids play a role?","volume":"62","author":"Sultan","year":"2008","journal-title":"Indian J. Med. Sci."},{"key":"ref_120","first-page":"36","article-title":"Vitamin D Deficiency in Adult Sickle Cell Patients","volume":"109","author":"Boettger","year":"2017","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00198-014-2773-7","article-title":"Bone mineral density in men and children with haemophilia A and B: A systematic review and meta-analysis","volume":"25","author":"Paschou","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.blre.2018.05.002","article-title":"Increased bone resorption in hemophilia","volume":"33","author":"Valentino","year":"2019","journal-title":"Blood Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e032891","DOI":"10.1136\/bmjopen-2019-032891","article-title":"Bone health in symptomatic carriers of haemophilia A: A protocol for a multicentre prospective matched-cohort study","volume":"9","author":"Tang","year":"2019","journal-title":"BMJ Open"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"201","DOI":"10.11005\/jbm.2017.24.4.201","article-title":"Bone Density Status in Bleeding Disorders: Where Are We and What Needs to be Done?","volume":"24","author":"Mansouritorghabeh","year":"2017","journal-title":"J. Bone Metab."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2516.2008.01963.x","article-title":"Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia","volume":"15","author":"Gerstner","year":"2009","journal-title":"Haemophilia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH09-09-0629","article-title":"Bone mineral density in haemophilia patients. A meta-analysis","volume":"103","author":"Iorio","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2516.2007.01533.x","article-title":"Pathogenesis of haemophilic synovitis: Clinical aspects","volume":"13","author":"Hoots","year":"2007","journal-title":"Haemophilia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1111\/j.1365-2516.2011.02514.x","article-title":"Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis","volume":"17","author":"Forsyth","year":"2011","journal-title":"Haemophilia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH11-08-05563","article-title":"Reduced bone mineral density in patients with haemophilia A and B in Northern Greece","volume":"107","author":"Anagnostis","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hae.12736","article-title":"Bone health in persons with haemophilia","volume":"21","author":"Kempton","year":"2015","journal-title":"Haemophilia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1160\/TH13-01-0030","article-title":"The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture","volume":"110","author":"Anagnostis","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.2012.01803.x","article-title":"Bone health in persons with haemophilia: A review","volume":"89","author":"Ghosh","year":"2012","journal-title":"Eur. J. Haematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/10\/3538\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:29:37Z","timestamp":1760174977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/10\/3538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":132,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21103538"],"URL":"https:\/\/doi.org\/10.3390\/ijms21103538","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]}}}